Form 8-K Jazz Pharmaceuticals For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
November 6, 2019 11:26 AM ESTOppenheimer analyst Esther Rajavelu raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $179.00 (from $176.00) while maintaining a Outperform rating.
The analyst commented, "We update our JAZZ model following 3Q19 results that topped our estimates for both revenue (Xyrem beat) and adjusted earnings.... More
